Plain-English translation of NCT06531278 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This clinical trial is testing a new treatment combination for pancreatic cancer that has spread to the liver. The study combines a medication called adebelimab with four standard chemotherapy drugs (liposomal irinotecan, , , and ). Researchers want to see if adding this new immunotherapy drug to the chemotherapy improves how well the treatment works and how safe it is for patients.
Pancreatic cancer is a serious disease, and when it spreads to the liver, the outlook is even more challenging. While current chemotherapy treatments help some patients, doctors are looking for better options. This medication is being tested because early research suggests it may work better than chemotherapy alone, potentially helping patients live longer.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive the new medication combination as your first treatment for pancreatic cancer with liver spread. The exact schedule of visits, tests, and how long you'll receive treatment will be explained by the research team. You'll have regular blood tests and imaging scans to monitor how well the treatment is working and to check for any side effects. The study plans to enroll 40 participants total.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
China